Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Marrocco, D. L., Tilley, W. D., Bianco-Miotto, T., Evdokiou, A., Scher, H. I., Rifkind, R. A., Marks, P. A., Richon, V. M., Butler, L. M.Volume:
6
Language:
english
Journal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.MCT-06-0144
Date:
January, 2007
File:
PDF, 664 KB
english, 2007